Abbott (ABT) Provides Details on Restructuring Plan for Solvay's Pharma Unit; Sees Q3 Charge of $430M
Tweet Send to a Friend
In a Form 8-K, Abbott Labs (NYSE: ABT) announced a restructuring plan related to its acquisition of Solvay’s pharmaceuticals business ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE